[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Bispo Júnior RZ, Camargo OP: Prognostic factors in the survival of patients diagnosed with primary non-metastatic osteosarcoma with a poor response to neoadjuvant chemotherapy. Clinics (Sao Paulo); 2009;64(12):1177-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in the survival of patients diagnosed with primary non-metastatic osteosarcoma with a poor response to neoadjuvant chemotherapy.
  • INTRODUCTION: Identification of variables that determine the prognosis for osteosarcoma may enable stratification of patients into subgroups with better or worse risk of local recurrence, metastases and death due to the disease.
  • Discovery of such prognostic factors would permit selection of a subgroup of at-risk patients, with the aim of improving the therapeutic effectiveness.
  • OBJECTIVE: To identify prognostic factors related to local recurrence-free survival, metastasis-free survival and overall survival among patients with highly malignant primary osteosarcoma that was non-metastatic on diagnosis and had poor response to neoadjuvant chemotherapy.
  • RESULTS: The adverse factors that influenced the risk of local recurrence and the overall survival in univariate analysis were histological subtype other than osteoblastic (p = 0.017) and tumor size greater than 15 cm (p = 0.048).
  • In relation to metastasis-free survival, the non-osteoblastic subtype had a worse prognosis (p = 0.007).
  • The osteosarcoma histological type is a significant independent predictor for local recurrence-free survival, metastasis-free survival and overall survival.
  • [MeSH-major] Bone Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Epidemiologic Methods. Female. Humans. Male. Neoadjuvant Therapy. Prognosis. Risk Factors. Treatment Failure. Tumor Burden. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Dec 15;18(24):4016-27 [11118462.001]
  • [Cites] Ann Oncol. 2001 Aug;12(8):1145-50 [11583198.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Jan;24(1):27-30 [11902735.001]
  • [Cites] Eur J Cancer. 2002 Jun;38(9):1218-25 [12044509.001]
  • [Cites] Cancer. 2003 Jun 15;97(12):3068-75 [12784343.001]
  • [Cites] J Pediatr (Rio J). 2004 Jan-Feb;80(1):65-70 [14978552.001]
  • [Cites] J Bone Joint Surg Am. 1967 Jan;49(1):101-10 [5225072.001]
  • [Cites] Arch Pathol Lab Med. 1977 Jan;101(1):14-8 [299812.001]
  • [Cites] Cancer Treat Rep. 1978 Feb;62(2):193-7 [273474.001]
  • [Cites] Cancer. 1979 Jun;43(6):2163-77 [88251.001]
  • [Cites] J Bone Joint Surg Am. 1980 Sep;62(6):1027-30 [7000786.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1178-84 [3476688.001]
  • [Cites] Semin Diagn Pathol. 1987 Aug;4(3):212-36 [3313606.001]
  • [Cites] J Bone Joint Surg Am. 1990 Jun;72(5):643-53 [2355025.001]
  • [Cites] J Clin Oncol. 1990 Dec;8(12):1988-97 [2230890.001]
  • [Cites] Chir Organi Mov. 1990;75(1 Suppl):82-5 [2249566.001]
  • [Cites] Cancer. 1991 Aug 15;68(4):733-7 [1855172.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):60-6 [1884560.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):8-14 [1884563.001]
  • [Cites] J Clin Oncol. 1992 Jan;10(1):5-15 [1370176.001]
  • [Cites] Cancer. 1992 Feb 1;69(3):698-708 [1730120.001]
  • [Cites] Int Orthop. 1992;16(1):55-8 [1572772.001]
  • [Cites] Orthopedics. 1992 May;15(5):599-604 [1589352.001]
  • [Cites] J Clin Oncol. 1992 Oct;10(10):1579-91 [1403038.001]
  • [Cites] Int J Cancer. 1993 Aug 19;55(1):44-50 [8344751.001]
  • [Cites] Cancer. 1993 Dec 1;72(11):3227-38 [8242546.001]
  • [Cites] J Clin Oncol. 1994 Feb;12(2):423-31 [8113851.001]
  • [Cites] Cancer. 1995 Jan 1;75(1 Suppl):203-10 [8000997.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):848-58 [8622033.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):76-84 [8996127.001]
  • [Cites] Acta Orthop Scand Suppl. 1997 Feb;273:156-60 [9057608.001]
  • [Cites] Lancet. 1997 Sep 27;350(9082):911-7 [9314869.001]
  • [Cites] Ann Oncol. 1998 Aug;9(8):893-9 [9789613.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1161-8 [16505436.001]
  • [Cites] Clinics (Sao Paulo). 2006 Apr;61(2):99-106 [16680325.001]
  • [Cites] Clinics (Sao Paulo). 2006 Oct;61(5):381-6 [17072434.001]
  • [Cites] Clinics (Sao Paulo). 2008 Apr;63(2):157-64 [18438568.001]
  • [Cites] Eur J Cancer. 2009 Sep;45(13):2367-75 [19349163.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(1):32-8 [11165127.001]
  • (PMID = 20037705.001).
  • [ISSN] 1980-5322
  • [Journal-full-title] Clinics (São Paulo, Brazil)
  • [ISO-abbreviation] Clinics (Sao Paulo)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Brazil
  • [Other-IDs] NLM/ PMC2797586
  • [Keywords] NOTNLM ; Bone neoplasms / Drug therapy / Epidemiology / Pathology / Surgery
  •  go-up   go-down


2. Labrinidis A, Hay S, Liapis V, Ponomarev V, Findlay DM, Evdokiou A: Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin Cancer Res; 2009 May 15;15(10):3451-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model.
  • PURPOSE: To evaluate the efficacy of zoledronic acid (ZOL) against osteosarcoma (OS) growth, progression, and metastatic spread using an animal model of human OS that closely resembles the human disease.
  • Tumor growth at the primary site and as pulmonary metastases was monitored by bioluminescence imaging and histology, and OS-induced bone destruction was measured using high-resolution micro-computed tomography.
  • Importantly, ZOL failed to reduce lung metastasis and in some cases was associated with larger and more numerous metastatic lesions.
  • Moreover, lung metastases were not reduced and may even have been promoted by this treatment, indicating that caution is required when the clinical application of the bisphosphonate class of antiresorptives is considered in OS.
  • [MeSH-major] Diphosphonates / pharmacology. Imidazoles / pharmacology. Osteoblasts / drug effects. Osteolysis / prevention & control. Osteosarcoma / drug therapy
  • [MeSH-minor] Animals. Apoptosis / drug effects. Bone Density Conservation Agents / pharmacology. Cell Line, Tumor. Cell Proliferation / drug effects. Disease Progression. Dose-Response Relationship, Drug. Female. Green Fluorescent Proteins / genetics. Green Fluorescent Proteins / metabolism. Humans. Luciferases / genetics. Luciferases / metabolism. Luminescent Measurements / methods. Mice. Mice, Inbred BALB C. Mice, Nude. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / metabolism. Tibia / drug effects. Tibia / pathology. Tumor Burden / drug effects. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Osteosarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast. 2003 Aug;12 Suppl 2:S37-44 [14659142.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):584-93 [12154351.001]
  • [Cites] Int J Cancer. 2008 Feb 15;122(4):751-60 [17960623.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3434-7 [11454892.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1581-7 [9362425.001]
  • [Cites] Crit Rev Eukaryot Gene Expr. 2000;10(2):159-78 [11186331.001]
  • [Cites] Annu Rev Biochem. 1996;65:241-69 [8811180.001]
  • [Cites] Cancer Res. 2002 Nov 1;62(21):6015-20 [12414621.001]
  • [Cites] Cancer Res. 2001 Mar 15;61(6):2602-8 [11289137.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):8-14 [1884563.001]
  • [Cites] Br J Cancer. 2002 Jul 29;87(3):366-71 [12177810.001]
  • [Cites] Acta Orthop Scand Suppl. 1997 Feb;273:120-5 [9057601.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):295-306 [12538482.001]
  • [Cites] Bone. 1985;6(6):433-7 [2937428.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):3054-8 [10898351.001]
  • [Cites] J Bone Miner Res. 2001 Nov;16(11):2027-34 [11697798.001]
  • [Cites] Calcif Tissue Res. 1975 Sep 5;18(3):215-31 [810231.001]
  • [Cites] Int J Hematol. 2004 Jan;79(1):37-43 [14979476.001]
  • [Cites] Pediatr Blood Cancer. 2004 May;42(5):410-5 [15049011.001]
  • [Cites] J Clin Invest. 2001 May;107(10):1219-20 [11375409.001]
  • [Cites] J Natl Cancer Inst. 2007 Feb 21;99(4):322-30 [17312309.001]
  • [Cites] Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3263-70 [18089720.001]
  • [Cites] Cancer Res. 2002 Oct 1;62(19):5564-70 [12359769.001]
  • [Cites] Breast Cancer Res. 2002;4(1):18-23 [11879555.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2522-9 [16270320.001]
  • [Cites] Calcif Tissue Res. 1973 Mar 12;11(3):196-214 [4707191.001]
  • [Cites] Cancer Res. 1993 Oct 15;53(20):4890-5 [8402677.001]
  • [Cites] Bone. 1994 Mar-Apr;15(2):161-6 [8086233.001]
  • [Cites] Oncologist. 2004;9 Suppl 4:3-13 [15459425.001]
  • [Cites] In Vitro Cell Dev Biol Anim. 2004 Mar-Apr;40(3-4):113-7 [15311969.001]
  • [Cites] Bibl Haematol. 1975 Oct;(43):84-7 [183736.001]
  • [Cites] J Immunol. 1996 Jan 15;156(2):611-20 [8543812.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 May;31(5):740-51 [15014901.001]
  • [Cites] Cancer Res. 2006 May 15;66(10):5363-70 [16707463.001]
  • [Cites] Anticancer Drugs. 2003 Oct;14(9):767-71 [14551512.001]
  • [Cites] Calcif Tissue Int. 1983;35(1):87-99 [6839194.001]
  • [Cites] Bone. 2005 Jul;37(1):74-86 [15894525.001]
  • [Cites] Bone. 2003 Aug;33(2):216-28 [14499355.001]
  • [Cites] Clin Cancer Res. 2009 Mar 15;15(6):1998-2009 [19276263.001]
  • [Cites] J Natl Cancer Inst. 1997 Nov 19;89(22):1706-15 [9390540.001]
  • [Cites] Anticancer Drugs. 2001 Jun;12(5):459-65 [11395574.001]
  • [Cites] Cancer. 2000 Jun 15;88(12 Suppl):2903-8 [10898332.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12 ):1971-8 [12799645.001]
  • (PMID = 19401351.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA008748
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bone Density Conservation Agents; 0 / Diphosphonates; 0 / Imidazoles; 0 / Recombinant Fusion Proteins; 147336-22-9 / Green Fluorescent Proteins; 6XC1PAD3KF / zoledronic acid; EC 1.13.12.- / Luciferases
  •  go-up   go-down


3. Muff R, Nigg N, Gruber P, Walters D, Born W, Fuchs B: Altered morphology, nuclear stability and adhesion of highly metastatic derivatives of osteoblast-like SAOS-2 osteosarcoma cells. Anticancer Res; 2007 Nov-Dec;27(6B):3973-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered morphology, nuclear stability and adhesion of highly metastatic derivatives of osteoblast-like SAOS-2 osteosarcoma cells.
  • BACKGROUND: Metastasis is the leading cause of death in patients with osteosarcoma (OS).
  • High alkaline phosphatase (ALP) activity and resistance to chemotherapy are independent predictors of poor clinical outcome of osteosarcoma.
  • Here, the osteoblastic phenotype, cell and nuclear morphology, cell adhesion and drug resistance of the SAOS-2 cell line and two in vivo selected highly metastatic derivatives, LM5 and LM7, were compared.
  • CONCLUSION: The increased metastatic potential of LM5 and LM7 as compared to SAOS-2 cells is not associated with a substantial change of the osteoblastic phenotype or of the cytotoxic response to current chemotherapeutic drugs.
  • The decrease in cell size and altered cell adhesion, reflecting cytoskeletal rearrangement, together with increased nuclear instability and partial dedifferentiation, as revealed by the loss of PTH responsiveness in LM7 cells, may account for the higher metastatic potential of the LM5 and LM7 sublines as compared to the parental SAOS-2 cells.
  • [MeSH-major] Bone Neoplasms / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Alkaline Phosphatase / metabolism. Cell Adhesion / physiology. Cell Line, Tumor. Cell Nucleus / pathology. Cisplatin / pharmacology. Cyclic AMP / biosynthesis. Doxorubicin / pharmacology. Drug Resistance, Neoplasm. Etoposide / pharmacology. Humans. Neoplasm Invasiveness. Osteoblasts / pathology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18225558.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; E0399OZS9N / Cyclic AMP; EC 3.1.3.1 / Alkaline Phosphatase; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Sakayama K, Fujibuchi T, Kidani T, Miyazaki T, Yamamoto H: Proliferative activity of osteosarcoma cells: comparison of osteoblastic and nonosteoblastic regions. J Orthop Sci; 2003;8(5):678-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proliferative activity of osteosarcoma cells: comparison of osteoblastic and nonosteoblastic regions.
  • There are two opinions regarding malignancy evaluation by location for osteoblastic osteosarcoma: One is that the nonosteoblastic region is undifferentiated and the degree of malignancy is high; the other is that the osteoblastic region sometimes shows a marked chemotherapy effect, so the degree of biological malignancy is higher.
  • The subjects were 10 patients with osteoblastic osteosarcoma at the distal region of the femur.
  • In all patients, the nonosteoblastic region showed a higher value than the osteoblastic region for both the PCNA labeling index and AgNORs number.
  • Both the PCNA-labeling index and AgNORs number in the metastatic foci were higher than in the primary lesions.
  • There are differences in proliferative ability in the intratumoral locations within the same osteoblastic osteosarcoma.
  • Moreover, there are differences in proliferative ability between the metastatic foci and the primary lesion.
  • [MeSH-major] Femoral Neoplasms / metabolism. Nucleolus Organizer Region / metabolism. Osteosarcoma / metabolism. Proliferating Cell Nuclear Antigen / metabolism

  • Genetic Alliance. consumer health - Osteosarcoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14557934.001).
  • [ISSN] 0949-2658
  • [Journal-full-title] Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association
  • [ISO-abbreviation] J Orthop Sci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Proliferating Cell Nuclear Antigen
  •  go-up   go-down


5. Okada K, Hasegawa T, Yokoyama R, Beppu Y, Itoi E: Osteosarcoma with cytokeratin expression: a clinicopathological study of six cases with an emphasis on differential diagnosis from metastatic cancer. J Clin Pathol; 2003 Oct;56(10):742-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma with cytokeratin expression: a clinicopathological study of six cases with an emphasis on differential diagnosis from metastatic cancer.
  • METHODS: Clinicopathological and immunohistochemical features were analysed in 131 patients with non-metastatic, conventional osteosarcoma, treated in Akita University and National Cancer Centre in Tokyo between 1972 and 1999.
  • Three tumours were classified as osteoblastic osteosarcoma, two as fibroblastic, and one as chondroblastic.
  • In three tumours classified as the osteoblastic subtype, epithelioid features were prominent, and four tumours showed pronounced cellular pleomorphism.
  • Preoperative and postoperative chemotherapy was given to five of the six patients, but the effects of these agents were negligible.
  • Three of the six patients developed lung metastases, whereas the other three patients have remained well with no evidence of local recurrence or distant metastasis.
  • CONCLUSIONS: Osteosarcoma with intense immunoreaction for cytokeratin was rare.
  • The clinicopathological features were similar to those of patients with conventional osteosarcoma, except for a higher age, chemotherapy resistance, histological epithelioid features, and pleomorphism.
  • This study indicates that osteoid formation and negative expression of epithelial membrane antigen are key features in the differentiation from metastatic carcinoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Bone Neoplasms / chemistry. Bone Neoplasms / secondary. Keratins / analysis. Osteosarcoma / chemistry. Osteosarcoma / secondary

  • Genetic Alliance. consumer health - Osteosarcoma.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2001 Jul;32(7):726-33 [11486171.001]
  • [Cites] Cancer. 1975 Dec;36(6):2179-91 [1060506.001]
  • [Cites] Hum Pathol. 1985 Dec;16(12):1235-42 [4065885.001]
  • [Cites] Am J Surg Pathol. 1985 Nov;9(11):791-7 [2416224.001]
  • [Cites] Hum Pathol. 1986 Oct;17(10):996-1008 [2428727.001]
  • [Cites] Cancer. 1987 Jan 1;59(1):134-41 [3539305.001]
  • [Cites] Cancer. 1989 Jul 1;64(1):43-51 [2731119.001]
  • [Cites] Acta Pathol Jpn. 1989 Jul;39(7):439-45 [2801114.001]
  • [Cites] Hum Pathol. 1991 Jun;22(6):583-90 [1864588.001]
  • [Cites] Arch Pathol Lab Med. 1993 Mar;117(3):295-8 [7680195.001]
  • [Cites] Cancer. 1993 May 15;71(10):2977-82 [7683966.001]
  • [Cites] Am J Surg Pathol. 1993 Apr;17(4):400-9 [8494106.001]
  • (PMID = 14514776.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC1770076
  •  go-up   go-down


6. Piscitelli D, Sanguedolce F, Mattioli E, Parisi G, Fiore MG, Resta L: [Unusual presentation of metastatic osteosarcoma as a giant duodenal polyp. A case report]. Pathologica; 2005 Apr;97(2):88-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Unusual presentation of metastatic osteosarcoma as a giant duodenal polyp. A case report].
  • [Transliterated title] Osteosarcoma metastatico polipoide del duodeno. descrizione di un caso ad insolita presentazione.
  • INTRODUCTION: Osteosarcoma is a malignant bone neoplasm with an usually high metastatic potential.
  • Besides the common metastatic sites such as lungs, bone, and pleura, metastases to unusual sites such as liver, brain and regional lymph nodes have also been reported with increasing frequency; among them, gastrointestinal metastases represent an extraordinarily rare event in the natural history of this neoplasia.
  • MATERIALS AND METHODS: We describe a case of a 27 year old man, who was diagnosed with a grade IV osteoblastic osteosarcoma of the left tibia and submitted to 5 courses of pre-surgical chemotherapy; later he underwent tibial resection with implantation of a prosthesis, followed by 2 further courses of adjuvant chemotherapy.
  • Due to alteration of the natural history of the tumor induced by multiagent chemotherapy, the rate of metastases of osteosarcoma to unusual sites has been increasing.
  • We report the 9th case of a gastrointestinal metastasis of osteosarcoma reported thus far, and only the second one arising in the duodenum.
  • Both the histological features and the immunohistochemical findings were not suggestive for osteosarcoma metastases because the tumor appeared dedifferentiated; in our case the combination of electron microscopy and clinical history played a pivotal role to establish the final diagnosis.
  • [MeSH-major] Bone Neoplasms / pathology. Duodenal Neoplasms / pathology. Duodenal Neoplasms / secondary. Osteosarcoma / secondary. Tibia

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16032954.001).
  • [ISSN] 0031-2983
  • [Journal-full-title] Pathologica
  • [ISO-abbreviation] Pathologica
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


7. Okada K, Hasegawa T, Yokoyama R, Beppu Y, Itoi E: Prognostic relevance of rosette-like features in osteosarcoma. J Clin Pathol; 2003 Nov;56(11):831-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic relevance of rosette-like features in osteosarcoma.
  • AIMS: To clarify the prognostic relevance of rosette-like features and other clinicopathological and immunohistochemical variables in patients with osteosarcoma.
  • METHODS: Clinicopathological and immunohistochemical variables were analysed in 131 patients with non-metastatic high grade conventional osteosarcoma, with particular attention to the prognostic impact of rosette-like features.
  • Rosette-like features were significantly associated with the osteoblastic subtype, numerous osteoclast-like giant cells, moderate pleomorphism, frequent haemangiopericytoma-like vascular patterns, epithelioid cytological features, positive immunoreactivity for epithelial membrane antigen and CD56, and negative staining for cytokeratin.
  • In a multivariate analysis, rosette-like features (relative risk (RR), 3.8), a poor chemotherapy effect (RR, 2.9), and a tumour size of 10 cm or more (RR, 2.8) were identified as unfavourable prognostic factors.
  • CONCLUSIONS: Rosette-like features can easily be identified from routine histological slides and the relative risk in patients with non-metastatic, conventional osteosarcoma is as high as other well known prognostic factors, including large size and poor chemotherapy effect.
  • [MeSH-major] Bone Neoplasms / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Humans. Multivariate Analysis. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1995 Nov 23;333(21):1380-5 [7477118.001]
  • [Cites] Cancer. 1995 Feb 1;75(3):806-14 [7828130.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):76-84 [8996127.001]
  • [Cites] Cancer Detect Prev. 1997;21(3):280-7 [9167046.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2095-106 [9179055.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2781-8 [10561353.001]
  • [Cites] J Surg Oncol. 2000 Feb;73(2):87-94 [10694644.001]
  • [Cites] Clin Orthop Relat Res. 2000 Apr;(373):39-50 [10810461.001]
  • [Cites] Hum Pathol. 2001 Jul;32(7):726-33 [11486171.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):776-90 [11821461.001]
  • [Cites] Semin Diagn Pathol. 1987 Aug;4(3):212-36 [3313606.001]
  • [Cites] Hum Pathol. 1991 Jun;22(6):583-90 [1864588.001]
  • [Cites] Cancer Res. 1992 Nov 15;52(22):6194-9 [1423262.001]
  • [Cites] Cancer. 1993 Feb 15;71(4):1224-30 [8435797.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1993;423(3):195-9 [8236813.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):848-58 [8622033.001]
  • (PMID = 14600127.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770098
  •  go-up   go-down


8. Bacci G, Mercuri M, Longhi A, Ferrari S, Bertoni F, Versari M, Picci P: Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer; 2005 Sep;41(14):2079-85
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution.
  • To determine whether necrosis induced by pre-operative chemotherapy correlates with the rate of systemic and local relapse, may change the pattern of relapse and/or may modify the chance of success of post-relapse treatments, we evaluated 881 patients with non-metastatic osteosarcoma of the extremities treated with five different protocols of neoadjuvant chemotherapy and surgery at the same institution between 1983 and 1999.
  • The 5-year disease-free survival (DFS) and overall survival (OS) correlated significantly with the histological response to chemotherapy.
  • The prognostic value of the histological response was valid only for osteoblastic and telangiectatic osteosarcoma subtypes.
  • Nonetheless, since they represent more than 70% of all osteosarcomas, we conclude that chemotherapy-induced necrosis has a significant prognostic value, regardless of the type of chemotherapy performed after surgery.
  • [MeSH-major] Bone Neoplasms / drug therapy. Osteosarcoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Extremities. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Preoperative Care / methods. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115755.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Ambroszkiewicz J, Gajewska J, Klepacka T, Bilska K, Woźniak W, Laskowska-Klita T: [Biochemical bone turnover markers in patients with conventional and nonconventional osteosarcoma]. Pol Merkur Lekarski; 2006 Oct;21(124):330-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Biochemical bone turnover markers in patients with conventional and nonconventional osteosarcoma].
  • They are considered to be useful in diagnosis and treatment of many metastatic bone diseases and primary osseous tumours.
  • THE AIM: of the study was to assess bone turnover markers in patients with conventional and nonconventional osteosarcoma during treatment.
  • MATERIAL AND METHODS: We examined 55 patients (5-20 years) with osteosarcoma.
  • Among patients with most frequent conventional osteosarcoma distinguished histological subtypes.
  • Bone turnover markers were determined in serum by immunoenzymatic assay at diagnosis, during preoperative- and postoperative chemotherapy and then after treatment.
  • RESULTS: We found different values of bone turnover markers in serum of patients with conventional osteosarcoma.
  • The highest activity of bone alkaline phosphatase and collagen type I crosslinked C-telopeptide in children with osteoblastic subtype of osteosarcoma were obtained.
  • The levels of tested parameters decreased about 20-40% during preoperative and postoperative chemotherapy, then they increased after treatment first of all in patients with chondroblastic subtype (p < 0.05).
  • Next we found that the osteocalcin concentration was 4-fold lower, in nonconventional osteosarcoma in comparison to the conventional.
  • This marker is stable during treatment and remains unchanged after it.
  • Moreover we showed that the changes of the bone alkaline phosphatase activity and the collagen type I crosslinked C-telopeptide concentration during and after treatment were less dynamic in children with nonconventional osteosarcoma.
  • CONCLUSIONS: Observed changes of markers in various histological subtypes of osteosarcoma can indicate different rate of their bone turnover.
  • Changes observed during treatment are more dynamic in conventional than in nonconventional type of osteosarcoma.
  • [MeSH-major] Alkaline Phosphatase / blood. Biomarkers, Tumor / blood. Bone Neoplasms / blood. Bone Resorption / metabolism. Collagen Type I / blood. Osteocalcin / blood. Osteosarcoma / blood

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17205770.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Collagen Type I; 0 / Peptides; 0 / collagen type I trimeric cross-linked peptide; 104982-03-8 / Osteocalcin; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


10. Bramer JA, Abudu AA, Tillman RM, Carter SR, Sumathi VP, Grimer RJ: Pre- and post-chemotherapy alkaline phosphatase levels as prognostic indicators in adults with localised osteosarcoma. Eur J Cancer; 2005 Dec;41(18):2846-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre- and post-chemotherapy alkaline phosphatase levels as prognostic indicators in adults with localised osteosarcoma.
  • The prognostic value of alkaline phosphatase (AP) measured before and after chemotherapy, but before surgery was established in a retrospective survey of patients.
  • The patients were 18 years or older, with non-metastatic high-grade osteosarcoma.
  • Pre-chemotherapy AP was available in 89 cases, post-chemotherapy AP in 86 patients, and both in 71 cases.
  • Osteosarcoma subtype was predominantly conventional.
  • No correlation was found between subtype and chemotherapy response, local recurrence or survival.
  • Pre-chemotherapy AP was raised more in the osteoblastic subtype.
  • Post-chemotherapy AP and normalisation were the same among different subtypes.
  • Normal or High pre-chemotherapy AP correlated with better survival at 10 years (64% and 70%) than Very High pre-chemotherapy AP (37%, P = 0.005).
  • Post-chemotherapy AP correlated with survival (68%, 39% and 25% in the Normal, High and Very High group, P = 0.0007) and response to chemotherapy (P = 0.049).
  • A pre-chemotherapy AP above twice Normal correlated with worse survival.
  • If AP decreased after chemotherapy, but was still raised, survival was better, but still worse than if AP normalised.
  • A raised post-chemotherapy AP predicts poor chemotherapy response.
  • [MeSH-major] Alkaline Phosphatase / metabolism. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / metabolism. Bone Neoplasms / enzymology. Osteosarcoma / enzymology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16274987.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; EC 3.1.3.1 / Alkaline Phosphatase
  •  go-up   go-down


11. Hong S, Rha S, Jeong J, Lee Y, Shin S, Shin K, Roh J: Comparison of long-term outcome between doublet versus triplet neoadjuvant chemotherapy in nonmetastatic osteosarcoma of extremity. J Clin Oncol; 2009 May 20;27(15_suppl):10542

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of long-term outcome between doublet versus triplet neoadjuvant chemotherapy in nonmetastatic osteosarcoma of extremity.
  • : 10542 Background: Multimodal approach had improved outcomes of non-metastatic osteosarcoma.
  • This study was to compare outcomes between doublet (AP; doxorubicin and cisplatin) and triplet (IAP; AP and ifosfamide) neoadjuvant chemotherapy for non-meteastatic osteosarcoma of extremity in a single institute.
  • METHODS: A total of 124 osteosarcoma patients were enrolled.
  • After completion of 3 cycles of chemotherapy, patients underwent limb-salvage surgery.
  • We assessed tumor response according to pathologic tumor necrosis, and treated further adjuvant chemotherapy.
  • In IAP group, all patients had 3 more cycles of IAP chemotherapy.
  • The most frequent site and histology were distal femur and osteoblastic type.
  • In toxicity profiles, there were more hematologic toxicity in IAP group (febrile neutropenia,p<0.001; thrombocytopenia,p<0.05), while there were no statistical differences in treatment related death.
  • CONCLUSIONS: The addition of ifosfamide to doxorubicin and cisplatin in neoadjuvant chemotherapy did not show improved outcomes in this study.
  • Further trials are required to elucidate optimal neoadjuvant chemotherapy and effective salvage regimens.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963960.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Dieudonné FX, Marion A, Haÿ E, Marie PJ, Modrowski D: High Wnt signaling represses the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells. Cancer Res; 2010 Jul 1;70(13):5399-408
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High Wnt signaling represses the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells.
  • Osteosarcoma is characterized by frequent relapse and metastatic disease associated with resistance to chemotherapy.
  • We previously showed that syndecan-2 is a mediator of the antioncogenic effect of chemotherapeutic drugs.
  • The purpose of this work was to elucidate molecular mechanisms responsible for the low expression of syndecan-2 in osteosarcoma.
  • We compared the regulatory activity of cis-acting DNA sequences of the syndecan-2 gene in osteosarcoma and osteoblastic cell lines.
  • We identified a DNA region that negatively regulates syndecan-2 transcription in the osteosarcoma cells.
  • The alteration of syndecan-2 expression in osteosarcoma cell lines also seemed to be related to a higher shedding, controlled by Wnt/RhoA.
  • These data identify a molecular network that may contribute to the low expression of the proapoptotic proteoglycan syndecan-2 in osteosarcoma cells.
  • The high activity of the canonical Wnt pathway in the different osteosarcoma cells induces a constitutive repression of syndecan-2 transcription, whereas Wnt/RhoA signaling blocks the amplification loop of syndecan-2 expression.
  • Our results identify syndecan-2 as a Wnt target and bring new insights into a possible pathologic role of Wnt signaling in osteosarcoma.
  • [MeSH-major] Bone Neoplasms / genetics. Osteosarcoma / genetics. Syndecan-2 / genetics. Wnt Proteins / metabolism

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • (PMID = 20530678.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / LEF1 protein, human; 0 / Lymphoid Enhancer-Binding Factor 1; 0 / Wnt Proteins; 124671-05-2 / RHOA protein, human; 149769-25-5 / Syndecan-2; EC 3.6.5.2 / rhoA GTP-Binding Protein
  •  go-up   go-down


13. He BC, Chen L, Zuo GW, Zhang W, Bi Y, Huang J, Wang Y, Jiang W, Luo Q, Shi Q, Zhang BQ, Liu B, Lei X, Luo J, Luo X, Wagner ER, Kim SH, He CJ, Hu Y, Shen J, Zhou Q, Rastegar F, Deng ZL, Luu HH, He TC, Haydon RC: Synergistic antitumor effect of the activated PPARgamma and retinoid receptors on human osteosarcoma. Clin Cancer Res; 2010 Apr 15;16(8):2235-45
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synergistic antitumor effect of the activated PPARgamma and retinoid receptors on human osteosarcoma.
  • PURPOSE: Osteosarcoma is the most common primary malignancy of bone.
  • The long-term survival of osteosarcoma patients hinges on our ability to prevent and/or treat recurrent and metastatic lesions.
  • Here, we investigated the activation of peroxisome proliferator-activated receptor gamma (PPARgamma) and retinoid receptors as a means of differentiation therapy for human osteosarcoma.
  • EXPERIMENTAL DESIGN: We examined the endogenous expression of PPARgamma and retinoid receptors in a panel of osteosarcoma cells.
  • Ligands or adenovirus-mediated overexpression of these receptors were tested to inhibit proliferation and induce apoptosis of osteosarcoma cells.
  • Osteosarcoma cells overexpressing the receptors were introduced into an orthotopic tumor model.
  • The effect of these ligands on osteoblastic differentiation was further investigated.
  • RESULTS: Endogenous expression of PPARgamma and isotypes of retinoic acid receptor (RAR) and retinoid X receptor (RXR) is detected in most osteosarcoma cells.
  • Troglitazone, 9-cis retinoic acid (RA), and all-trans RA, as well as overexpression of PPARgamma, RARalpha, and RXRalpha, inhibit osteosarcoma cell proliferation and induce apoptosis.
  • A synergistic inhibitory effect on osteosarcoma cell proliferation is observed between troglitazone and retinoids, as well as with the overexpression pairs of PPARgamma/RARalpha, or PPARgamma/RXRalpha.
  • Overexpression of PPARgamma, RARalpha, RXRalpha, or in combinations inhibits osteosarcoma tumor growth and cell proliferation in vivo.
  • Retinoids (and to a lesser extent, troglitazone) are shown to promote osteogenic differentiation of osteosarcoma cells and mesenchymal stem cells.
  • CONCLUSIONS: Activation of PPARgamma, RARalpha, and RXRalpha may act synergistically on inhibiting osteosarcoma cell proliferation and tumor growth, which is at least partially mediated by promoting osteoblastic differentiation of osteosarcoma cells.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Bone Neoplasms / metabolism. Osteosarcoma / metabolism. PPAR gamma / metabolism. Receptors, Retinoic Acid / metabolism. Retinoid X Receptors / metabolism
  • [MeSH-minor] Adenoviridae / genetics. Animals. Apoptosis / drug effects. Blotting, Western. Cell Differentiation / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Drug Synergism. Humans. Luciferases / metabolism. Mesenchymal Stromal Cells / cytology. Mesenchymal Stromal Cells / drug effects. Mesenchymal Stromal Cells / metabolism. Mice. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tretinoin / pharmacology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20371684.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / AR054381; United States / NIAMS NIH HHS / AR / AR50142; United States / NCCIH NIH HHS / AT / AT004418; United States / NCI NIH HHS / CA / CA106569
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / PPAR gamma; 0 / RNA, Messenger; 0 / Receptors, Retinoic Acid; 0 / Retinoid X Receptors; 0 / retinoic acid receptor alpha; 5688UTC01R / Tretinoin; EC 1.13.12.- / Luciferases
  •  go-up   go-down


14. Zafad S, Madani A, Harif M, Quessar A, Trachli A, Benchekroun S: [Multifocal osteosarcoma. A case report]. Arch Pediatr; 2000 Oct;7(10):1077-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multifocal osteosarcoma. A case report].
  • Multifocal osteosarcoma is an uncommon and aggressive presentation of osteosarcoma.
  • CASE REPORT: We report a case of multifocal osteosarcoma in a 12-year-old boy who was admitted for a tumor of the skull, associated with pleural and pulmonary nodules.
  • A computed tomography scan of the head showed a calcified lesion with intra- and extracranial extent.
  • A biopsy of the skull tumor showed an osteoblastic osteosarcoma.
  • Three weeks later, the patient developed two other tumors of the skull, a tumor of the left shoulder and a pelvic pain.
  • The patient was unresponsive to chemotherapy (high dose methotrexate and doxorubicin) and died nine months later.
  • COMMENTS: Multifocal osteosarcoma, or osteosarcomatosis, is a highly aggressive form of osteosarcoma.
  • The incidence is reported to be between 1 and 10% of osteosarcoma.
  • The histology shows an osteosarcoma of osteoblastic type in most cases.
  • CONCLUSION: Despite intensive chemotherapy, the prognosis remains poor.
  • The debate remains as to whether or not this clinical presentation represents true multifocality of the disease or a relatively unusual metastatic pattern of osteosarcoma.
  • [MeSH-major] Bone Neoplasms. Neoplasms, Multiple Primary. Osteosarcoma. Ribs. Scapula. Skull Neoplasms
  • [MeSH-minor] Child. Humans. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11075263.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] FRANCE
  •  go-up   go-down


15. Ham SJ, Kroon HM, Koops HS, Hoekstra HJ: Osteosarcoma of the pelvis--oncological results of 40 patients registered by The Netherlands Committee on Bone Tumours. Eur J Surg Oncol; 2000 Feb;26(1):53-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma of the pelvis--oncological results of 40 patients registered by The Netherlands Committee on Bone Tumours.
  • AIM AND METHODS: We reviewed the oncological outcome in 40 consecutive patients with an osteosarcoma of the pelvic region, registered in the files of the Netherlands Committee on Bone Tumours (NCBT) between 1978 and 1995.
  • RESULTS: Six patients had distant metastases at initial presentation (Enneking stage IIIB), 33 patients had stage IIB osteosarcoma and one patient stage IB osteosarcoma.
  • Patients with metastases were treated with chemotherapy (four) or palliative procedures (two).
  • Patients with non-metastatic osteosarcoma were treated with surgical procedures with (14) or without (four) neoadjuvant chemotherapy, chemotherapy without surgical resection (nine), or palliative procedures (seven).
  • The median survival of stage IIB and IIIB osteosarcoma was 14 months (2-175) and 7.5 months (2-16), respectively.
  • Survival in patients with stage IIB osteosarcoma treated with curative procedures was significantly better (P<0.0006) compared with stage IIB patients treated with palliative intent.
  • Two and 5-year survival for patients with curatively treated stage IIB osteosarcoma was 35% and 26%, respectively; distant metastases had developed in 65% of these patients.
  • On univariate analysis, positive prognostic factors for patients with stage IIB osteosarcoma were complaints of 3 months or less before initial presentation, tumour size of 8 cm or less, osteoblastic subtype, surgical resection of the primary tumour and limb salvage procedures.
  • CONCLUSION: In conclusion, the prognosis of pelvic osteosarcoma remained poor despite modern multimodality treatment regimens, including neoadjuvant chemotherapy.
  • [MeSH-major] Bone Neoplasms / therapy. Osteosarcoma / therapy. Pelvic Bones
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Hemipelvectomy. Humans. Male. Middle Aged. Neoplasm Staging. Netherlands. Prognosis. Registries. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10718181.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


16. Wengerkievicz AC, Corá AP, de Almeida LP, Duarte NJ, Siqueira SA, Antonangelo L: Neoplastic ascites in osteosarcoma: a case report. Acta Cytol; 2010 Sep-Oct;54(5 Suppl):845-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoplastic ascites in osteosarcoma: a case report.
  • BACKGROUND: Osteosarcoma is a malignant tumor of connective tissue whose tumor cells produce bone tissue.
  • It can be classified as osteoblastic, chondroblastic, or fibroblastic, according to the predominant histologic type of cells.
  • We present a case of osteosarcoma with peritoneal dissemination that developed neoplastic ascites.
  • Computed tomography showed blastic lesions in the L3 vertebral body.
  • Surgical resection and histologic analysis revealed a mixed osteoblastic and chondroblastic osteosarcoma.
  • After only one session of chemotherapy, the patient presented a marked clinical worsening with extensive metastatic dissemination and occurrence of voluminous ascites.
  • CONCLUSION: This case is the only report of osteosarcoma primarily focused on the vertebral column affected by peritoneal metastasis shown by cytologic examination of ascitic fluid.
  • [MeSH-major] Ascites / pathology. Osteosarcoma / pathology. Spinal Neoplasms / pathology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21053553.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Zou CY, Wang J, Shen JN, Huang G, Jin S, Yin JQ, Guo QC, Li HM, Luo L, Zhang M, Zhang LJ: Establishment and characteristics of two syngeneic human osteosarcoma cell lines from primary tumor and skip metastases. Acta Pharmacol Sin; 2008 Mar;29(3):325-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characteristics of two syngeneic human osteosarcoma cell lines from primary tumor and skip metastases.
  • AIM: To characterize and compare the different biological behaviors of 2 novel human osteosarcoma cell lines, Zos and Zos-M, established respectively from the primary tumor and the skip metastasis of an osteosarcoma patient.
  • METHODS: In vitro studies included morphological observations, karyotype analysis, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide cell proliferation assay, and cell sensitivity to chemotherapeutic drugs.
  • Subcutaneous and intravenous inoculations into nude mice were carried out to study the tumorigenicity and the metastatic potential.
  • RT-PCR was performed to assess the expression of the osteoblastic markers and some metastasis-related genes.
  • The RT-PCR examination indicated that they retained the molecular characteristics of an osteoblastic lineage.
  • Moreover, both cell lines are less sensitive to the current chemotherapy protocols.
  • CONCLUSION: The establishment of osteosarcoma cell lines, Zos and Zos-M, and related animal models provide a useful resource for studying the aggressive behavior of osteosarcoma and will be helpful for screening effective treatment strategies.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Osteosarcoma / pathology. Osteosarcoma / secondary
  • [MeSH-minor] Adolescent. Animals. Antimetabolites, Antineoplastic / pharmacology. Cell Line, Tumor. Cell Lineage. Cell Proliferation / drug effects. Collagen / metabolism. Drug Combinations. Extracellular Matrix / metabolism. Formazans / metabolism. Humans. Inhibitory Concentration 50. Karyotyping. Laminin / metabolism. Male. Methotrexate / pharmacology. Mice. Mice, Nude. Neoplasm Metastasis / pathology. Proteoglycans / metabolism. Tetrazolium Salts / metabolism. Xenograft Model Antitumor Assays

  • Genetic Alliance. consumer health - Osteosarcoma.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18298897.001).
  • [ISSN] 1745-7254
  • [Journal-full-title] Acta pharmacologica Sinica
  • [ISO-abbreviation] Acta Pharmacol. Sin.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / Drug Combinations; 0 / Formazans; 0 / Laminin; 0 / Proteoglycans; 0 / Tetrazolium Salts; 119978-18-6 / matrigel; 23305-68-2 / MTT formazan; 9007-34-5 / Collagen; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


18. Akiyama T, Dass CR, Choong PF: Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol Cancer Ther; 2008 Nov;7(11):3461-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway.
  • Osteosarcoma is the most common bone sarcoma, which mainly affects adolescents and young adults.
  • Although the combination of modern surgery and systemic chemotherapy has improved osteosarcoma treatment dramatically, no substantial change in survival has been seen over the past 20 years.
  • Therefore, novel therapeutic strategies for osteosarcoma are required if the 35% of patients with fatal metastases are to be successfully treated.
  • Recently, osteoclasts have drawn attention as a therapeutic target in various bone disorders including osteosarcoma.
  • Osteosarcoma cells are of the osteoblastic lineage, the latter of which is characterized by cells secreting the osteoclast-inducing factor, receptor activator of nuclear factor-kappaB ligand.
  • Hence, osteosarcoma is a better candidate for osteoclast-targeted therapy than other primary and metastatic bone tumors.
  • The rapid progress on the molecular mechanism regulating osteoclast has propelled a development of new therapeutic approaches.
  • In this review article, we present the prospects of osteoclast-targeted therapy as a novel treatment strategy for osteosarcoma.
  • [MeSH-major] Apoptosis. Bone Neoplasms / drug therapy. Bone Resorption. Osteoclasts / drug effects. Osteosarcoma / drug therapy


19. Staals EL, Bacchini P, Bertoni F: High-grade surface osteosarcoma: a review of 25 cases from the Rizzoli Institute. Cancer; 2008 Apr 1;112(7):1592-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade surface osteosarcoma: a review of 25 cases from the Rizzoli Institute.
  • BACKGROUND: High-grade surface osteosarcoma is a rare variant of surface osteosarcoma and is associated with a poor prognosis.
  • METHODS: This retrospective study includes all cases of high-grade surface osteosarcoma filed at the Rizzoli Institute.
  • All lesions demonstrated the histologic aspect of a high-grade osteosarcoma, 20 were osteoblastic, and 5 were chondroblastic.
  • Nineteen patients underwent a combination of surgery and chemotherapy for treatment of their initial lesion, whereas 5 patients were managed with surgery alone.
  • CONCLUSIONS: High-grade surface osteosarcoma is an extremely rare subtype of osteosarcoma.
  • Metastatic disease and limb-sacrificing surgery were associated with a worse prognosis.
  • Wide surgical excision and chemotherapy might improve the outcome.
  • [MeSH-major] Bone Neoplasms / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Cross-Sectional Studies. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / diagnosis. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18300258.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Brounais B, Chipoy C, Mori K, Charrier C, Battaglia S, Pilet P, Richards CD, Heymann D, Rédini F, Blanchard F: Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the antitumor effect of Midostaurin in vivo. Clin Cancer Res; 2008 Sep 1;14(17):5400-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncostatin M induces bone loss and sensitizes rat osteosarcoma to the antitumor effect of Midostaurin in vivo.
  • PURPOSE: In cultures, the cytokine oncostatin M (OSM) reduces the growth and induces differentiation of osteoblasts and osteosarcoma cells into glial/osteocytic cells.
  • EXPERIMENTAL DESIGN: Adenoviral gene transfer of OSM (AdOSM) was done in naive and osteosarcoma-bearing rats, alone or in combination with Midostaurin (PKC412), a derivative of staurosporine currently used in cancer clinical trials.
  • Bone variables were analyzed by micro-computed tomography scanner, by histology, and by the levels of various serum bone markers.
  • Osteosarcoma progression was analyzed by the development of the primary bone tumor, evolution of pulmonary metastasis, histology (necrosis and fibrosis), and animal survival.
  • RESULTS: In naive rats, AdOSM reduced serum osteoblastic and osteoclastic markers in correlation with a reduced trabecular bone volume.
  • In an osteosarcoma rat model, the combination of AdOSM with PKC412 reduced the progression of the primary bone tumor, pulmonary metastatic dissemination, and increased overall survival, whereas these agents alone had no antitumor effect.
  • Increased tumor necrosis and tissue repair (fibrosis) were observed with this combination.
  • CONCLUSION: These in vivo experiments confirm that systemic OSM overexpression alters osteoblast/osteosarcoma activity.
  • Because OSM sensitizes rat osteosarcoma to apoptosis/necrosis, the use of kinase inhibitors such as Midostaurin in association with OSM could represent new adjuvant treatments for this aggressive malignancy.
  • [MeSH-major] Bone Neoplasms / drug therapy. Oncostatin M / pharmacology. Osteosarcoma / drug therapy. Staurosporine / analogs & derivatives

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18765531.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 106956-32-5 / Oncostatin M; 120685-11-2 / 4'-N-benzoylstaurosporine; H88EPA0A3N / Staurosporine
  •  go-up   go-down


21. Anderson PM, Wiseman GA, Dispenzieri A, Arndt CA, Hartmann LC, Smithson WA, Mullan BP, Bruland OS: High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol; 2002 Jan 01;20(1):189-96
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.
  • PURPOSE: Samarium-153 ethylene diamine tetramethylene phosphonate ((153)Sm-EDTMP), a bone-seeking radiopharmaceutical, provides therapeutic irradiation to osteoblastic bone metastases.
  • Because the dose-limiting toxicity of (153)Sm-EDTMP is thrombocytopenia, a dose-escalation trial using peripheral-blood progenitor cells (PBPCs) or marrow support was conducted to treat metastatic bone cancer.
  • PATIENTS AND METHODS: Patients with locally recurrent or metastatic osteosarcoma or skeletal metastases avid on bone scan were treated with 1, 3, 4.5, 6, 12, 19, or 30 mCi/kg of (153)Sm-EDTMP.
  • CONCLUSION: (153)Sm-EDTMP with PBPC support can provide bone-specific therapeutic irradiation (estimates of 39 to 241 Gy).
  • [MeSH-major] Bone Neoplasms / radiotherapy. Bone Neoplasms / secondary. Neoplasm Recurrence, Local / drug therapy. Organometallic Compounds / therapeutic use. Organophosphorus Compounds / therapeutic use. Osteosarcoma / radiotherapy. Palliative Care / methods. Radioisotopes / therapeutic use. Samarium / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Child. Dose-Response Relationship, Drug. Hematologic Diseases / etiology. Hematologic Diseases / therapy. Humans. Maximum Tolerated Dose. Middle Aged. Tissue Distribution


22. Basaria S, McCarthy EF, Belzberg AJ, Ball DW: Case of an ivory vertebra. J Endocrinol Invest; 2000 Sep;23(8):533-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The differential diagnosis of an osteoblastic vertebral lesion (ivory vertebra) includes metastatic prostate cancer, lung cancer, lymphoma, osteosarcoma and Paget's disease.
  • He failed to respond to conventional bisphosphate therapy.
  • The review of the original biopsy specimen showed metastatic carcinoid tumor involving the bone marrow.
  • [MeSH-minor] Alendronate / therapeutic use. Alkaline Phosphatase / blood. Biopsy. Bone Marrow / pathology. Diagnosis, Differential. Diphosphonates / therapeutic use. Humans. Lumbar Vertebrae. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Metastasis. Osteitis Deformans / drug therapy. Osteoblasts / pathology. Technetium. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Alendronic acid .
  • Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 1973 May;107(2):327-30 [4695897.001]
  • [Cites] Anticancer Res. 1998 Mar-Apr;18(2B):1243-9 [9615795.001]
  • [Cites] Thorax. 1977 Aug;32(4):509-11 [929495.001]
  • [Cites] Clin Exp Rheumatol. 1994 Mar-Apr;12(2):228-9 [8039297.001]
  • [Cites] Skeletal Radiol. 1991;20(2):149-51 [2020865.001]
  • [Cites] Clin Biochem. 1987 Aug;20(4):225-30 [3319285.001]
  • (PMID = 11021770.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Diphosphonates; 7440-26-8 / Technetium; EC 3.1.3.1 / Alkaline Phosphatase; OYY3447OMC / pamidronate; X1J18R4W8P / Alendronate
  •  go-up   go-down


23. Fernandes R, Nikitakis NG, Pazoki A, Ord RA: Osteogenic sarcoma of the jaw: a 10-year experience. J Oral Maxillofac Surg; 2007 Jul;65(7):1286-91
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Head and neck OS are associated with a lower metastatic rate than long bone OS, and they have a better 5-year survival rate, ranging between 27% and 84%.
  • The main histologic subtype was chondroblastic (8 cases), followed by osteoblastic (4 cases).
  • Overall, the primary treatment modality consisted of surgery in all 14 patients treated at the University of Maryland; 2 patients opted for treatment at other institutions.
  • Chemotherapy, consisting primarily of cisplatin and Adriamycin (doxorubicin hydrochloride; Pharmacia, Kalamazoo, MI), was used as adjuvant treatment in 4 cases of high-grade OS.
  • [MeSH-major] Jaw Neoplasms / pathology. Osteosarcoma / pathology
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / therapeutic use. Doxorubicin / therapeutic use. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Retrospective Studies

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577490.001).
  • [ISSN] 0278-2391
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


24. Vigneswaran N, Fernandes R, Rodu B, Baughman RA, Siegal GP: Aggressive osteoblastoma of the mandible closely simulating calcifying epithelial odontogenic tumor. Report of two cases with unusual histopathologic findings. Pathol Res Pract; 2001;197(8):569-76
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aggressive osteoblastoma is a rare bone-forming neoplasm composed of prominent epithelioid cells that demonstrate locally invasive growth with a high rate of recurrence but no metastatic potential.
  • Both tumors were resected with wide surgical margins and neither patient had adjuvant radiation or chemotherapy.
  • Differentiation of this tumor from histologically similar calcifying epithelial odontogenic tumor and low-grade osteosarcoma proved difficult.
  • Immunohistochemical study with osteocalcin confirmed the osteoblastic nature of these epithelioid cells.

  • Genetic Alliance. consumer health - Calcifying Epithelial Odontogenic Tumor.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11518051.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Vimentin; 104982-03-8 / Osteocalcin
  •  go-up   go-down






Advertisement